Holen Sie sich die Stockscreener-App
210.23
1.95%
-4.19
Handel nachbörslich:
210.50
0.27
+0.13%
Schlusskurs vom Vortag:
$214.42
Offen:
$214.25
24-Stunden-Volumen:
636.18K
Relative Volume:
0.72
Marktkapitalisierung:
$13.65B
Einnahmen:
$4.44B
Nettoeinkommen (Verlust:
$29.49M
KGV:
-11,425.54
EPS:
-0.0184
Netto-Cashflow:
$1.19B
1W Leistung:
-3.75%
1M Leistung:
-13.70%
6M Leistung:
+6.27%
1J Leistung:
+56.60%
1-Tages-Spanne:
$208.15
$214.78
1-Wochen-Bereich:
$208.15
$221.99
52-Wochen-Spanne:
$128.80
$266.38
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Firmenname
Jazz Pharmaceuticals Plc
Sektor
Branche
Telefon
353-1-634-7800
Adresse
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
210.23 | 13.65B | 4.44B | 29.49M | 1.19B | -0.0184 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-30 | Eingeleitet | Citigroup | Buy |
| 2026-09-24 | Fortgesetzt | Goldman | Buy |
| 2026-07-17 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-06-09 | Fortgesetzt | Truist | Buy |
| 2026-05-22 | Eingeleitet | Bernstein | Mkt Perform |
| 2026-05-19 | Hochstufung | UBS | Neutral → Buy |
| 2026-04-10 | Fortgesetzt | Raymond James | Outperform |
| 2026-02-27 | Eingeleitet | Barclays | Overweight |
| 2025-11-24 | Herabstufung | UBS | Buy → Neutral |
| 2025-07-15 | Eingeleitet | Deutsche Bank | Buy |
| 2025-03-07 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-26 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Eingeleitet | Goldman | Buy |
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-11-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-06-12 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-12-09 | Hochstufung | Goldman | Neutral → Buy |
| 2022-06-14 | Eingeleitet | UBS | Buy |
| 2022-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-11-19 | Fortgesetzt | Goldman | Buy |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-10-05 | Eingeleitet | Citigroup | Buy |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-05-19 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-11-03 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-14 | Herabstufung | Goldman | Neutral → Sell |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Eingeleitet | Jefferies | Buy |
| 2020-03-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Neutral |
| 2019-08-21 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2018-12-14 | Eingeleitet | Wolfe Research | Peer Perform |
| 2018-11-08 | Bestätigt | B. Riley FBR | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2018-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Bestätigt | H.C. Wainwright | Neutral |
| 2018-03-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Jazz Pharmaceuticals Plc Aktie (JAZZ) Neueste Nachrichten
HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth? - Zacks Investment Research
Jim Cramer Gives Green Light To This Health Care Stock - Benzinga
Jazz Pharmaceuticals (JAZZ) President & CEO Renee Gala Sells 2,0 - GuruFocus
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock - Zacks Investment Research
Jazz Pharmaceuticals plc (J7Z.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
The top 12 companies hiring in biopharma now - BioSpace
Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks - Yahoo Finance
What Comes Next for Jazz Pharmaceuticals (NASDAQ:JAZZ)? - Kalkine Media
Jazz Pharmaceuticals plc (JAZZ) stock price, news, quote and history - Yahoo Finance Singapore
Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B - Yahoo Finance
Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands - Yahoo Finance
What Makes the Latest Jazz Pharmaceuticals (JAZZ) Story Different? - Kalkine Media
Ajit Baid Joins Jazz Pharmaceuticals as Executive Director, Head of Marketing – EMD Franchise - hrtoday.in
Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition? - Yahoo Finance
Jazz Pharmaceuticals (JAZZ) Places An $820M Epilepsy Bet - Yahoo Finance
Jazz Pharmaceuticals Completes $820 Million Acquisition of Actio Biosciences - BioBuzz
Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences - PR Newswire
Jazz Pharmaceuticals (JAZZ) Wins On Ziihera Data, Is It Still 15% Below Fair Value? - simplywall.st
Jazz Pharmaceuticals (JAZZ) Wins On Ziihera Data, Is It Still 15% Below Fair Value? - simplywall.st
ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks - TradingView
Jazz Pharmaceuticals Sees Meaningful Long-Term Value From Ziihera's Pursuits Beyond GEA, UBS Says - marketscreener.com
JAZZ Maintained by UBS -- Price Target Raised to $337 - GuruFocus
UBS raises Jazz Pharmaceuticals stock price target on Ziihera approval - Investing.com
UBS raises Jazz Pharmaceuticals stock price target on Ziihera approval By Investing.com - Investing.com India
UBS raises Jazz Pharmaceuticals stock price target on Ziihera approval By Investing.com - Investing.com UK
UBS Adjusts Jazz Pharmaceuticals PT to $337 From $315, Maintains Buy Rating - marketscreener.com
ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks - tradingview.com
2 Reasons to Avoid JAZZ and 1 Stock to Buy Instead - Yahoo Finance
UBS raises Jazz Pharmaceuticals stock price target on Ziihera approval By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals SVP Mary Elizabeth Henderson Sells Shares to Cover RSU Tax Withholding - Kalkine Media
Jazz Pharmaceuticals (NASDAQ: JAZZ) exec to sell restricted stock - Stock Titan
Jazz Pharmaceuticals at citigroup summit: rare-disease push gains pace By Investing.com - Investing.com Nigeria
JAZZ: Record growth, new launches, and AI-driven strategies fuel rare disease expansion and raised outlook - TradingView
Jazz Pharmaceuticals at citigroup summit: rare-disease push gains pace - Investing.com
Jazz Pharmaceuticals at citigroup summit: rare-disease push gains pace By Investing.com - Investing.com UK
JAZZ Maintained by Barclays -- Price Target Raised to $271 - GuruFocus
Jazz Pharmaceuticals at Wells Fargo conference: growth broadens By Investing.com - Investing.com India
Jazz Pharmaceuticals at Wells Fargo conference: growth broadens By Investing.com - Investing.com Canada
Jazz Pharmaceuticals at Wells Fargo conference: growth broadens By Investing.com - Investing.com UK
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery By Investing.com - Investing.com Australia
Jazz Pharmaceuticals (JAZZ) Stock Looks Reasonable On Value While Returns Look Stretched - simplywall.st
Jazz Pharmaceuticals (JAZZ) Stock Looks Reasonable On Value While Returns Look Stretched - simplywall.st
JAZZ: Record revenue, pipeline expansion, and rare disease focus drive strong growth outlook - TradingView
Jazz Pharma (NASDAQ: JAZZ) exec plans $486K Rule 144 stock sale - Stock Titan
Jazz Pharmaceuticals (JAZZ) director moves to sell more stock - Stock Titan
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery - Investing.com Nigeria
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery - Investing.com India
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery - Investing.com South Africa
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery - Investing.com Canada
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery - investing.com
Finanzdaten der Jazz Pharmaceuticals Plc-Aktie (JAZZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
Jazz Pharmaceuticals Plc-Aktie (JAZZ) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GALA RENEE D | President & CEO |
Oct 06 '26 |
Sale |
236.40 |
2,000 |
472,800 |
141,394 |
| RENEE D GALA | Officer |
Oct 06 '26 |
Proposed Sale |
236.40 |
2,000 |
472,800 |
0 |
| COZADD BRUCE C | Director |
Oct 01 '26 |
Sale |
230.33 |
6,000 |
1,381,980 |
345,875 |
| Bruce C Cozadd | Officer |
Oct 01 '26 |
Proposed Sale |
230.33 |
6,000 |
1,381,980 |
0 |
| Patil Neena M | EVP & Chief Legal Officer |
Sep 10 '26 |
Sale |
240.94 |
1,200 |
289,128 |
47,671 |
| NEENA PATIL | Officer |
Sep 10 '26 |
Proposed Sale |
240.94 |
1,200 |
289,128 |
0 |
| GALA RENEE D | President & CEO |
Sep 08 '26 |
Sale |
243.03 |
2,000 |
486,060 |
143,394 |
| RENEE D GALA | Officer |
Sep 08 '26 |
Proposed Sale |
243.03 |
2,000 |
486,060 |
0 |
| Henderson Mary Elizabeth | Director |
Sep 08 '26 |
Proposed Sale |
246.81 |
2,691 |
664,166 |
0 |
| COZADD BRUCE C | Director |
Sep 01 '26 |
Sale |
250.13 |
6,000 |
1,500,780 |
351,875 |
0.27%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):